234 related articles for article (PubMed ID: 9170429)
41. Combined fluorine-18-FDG and carbon-11-methionine PET for diagnosis of tumors in lung and mediastinum.
Nettelbladt OS; Sundin AE; Valind SO; Gustafsson GR; Lamberg K; Långström B; Björnsson EH
J Nucl Med; 1998 Apr; 39(4):640-7. PubMed ID: 9544671
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET.
Fukunaga T; Okazumi S; Koide Y; Isono K; Imazeki K
J Nucl Med; 1998 Jun; 39(6):1002-7. PubMed ID: 9627333
[TBL] [Abstract][Full Text] [Related]
43. Carbon-11-thymidine and FDG to measure therapy response.
Shields AF; Mankoff DA; Link JM; Graham MM; Eary JF; Kozawa SM; Zheng M; Lewellen B; Lewellen TK; Grierson JR; Krohn KA
J Nucl Med; 1998 Oct; 39(10):1757-62. PubMed ID: 9776283
[TBL] [Abstract][Full Text] [Related]
44. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose.
Dehdashti F; Siegel BA; Griffeth LK; Fusselman MJ; Trask DD; McGuire AH; McGuire DJ
Radiology; 1996 Jul; 200(1):243-7. PubMed ID: 8657920
[TBL] [Abstract][Full Text] [Related]
45. Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues.
Paquet N; Albert A; Foidart J; Hustinx R
J Nucl Med; 2004 May; 45(5):784-8. PubMed ID: 15136627
[TBL] [Abstract][Full Text] [Related]
46. [Standard uptake value of 18F-fluorine-2-deoxyglucose is correlated with the expression of estrogen receptor in duct carcinoma of breast].
Wen GH; Feng YL; Deng HF; Yu FZ; Liu DJ; Yuan JW; He XH; Huang KM; Liu SS; Yang M
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 May; 39(3):448-50. PubMed ID: 18575338
[TBL] [Abstract][Full Text] [Related]
47. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas.
Nakamoto Y; Higashi T; Sakahara H; Tamaki N; Kogire M; Doi R; Hosotani R; Imamura M; Konishi J
Cancer; 2000 Dec; 89(12):2547-54. PubMed ID: 11135214
[TBL] [Abstract][Full Text] [Related]
48. Detection of oral dysplasia in animals with fluorine-18-FDG and carbon-11-tyrosine.
Braams JW; Witjes MJ; Nooren CA; Nikkels PG; Vaalburg W; Vermey A; Roodenburg JL
J Nucl Med; 1998 Aug; 39(8):1476-80. PubMed ID: 9708533
[TBL] [Abstract][Full Text] [Related]
49. Influence of the blood glucose concentration on FDG uptake in cancer--a PET study.
Lindholm P; Minn H; Leskinen-Kallio S; Bergman J; Ruotsalainen U; Joensuu H
J Nucl Med; 1993 Jan; 34(1):1-6. PubMed ID: 8418248
[TBL] [Abstract][Full Text] [Related]
50. Role of Optimal Quantification of FDG PET Imaging in the Clinical Practice of Radiology.
Ziai P; Hayeri MR; Salei A; Salavati A; Houshmand S; Alavi A; Teytelboym OM
Radiographics; 2016; 36(2):481-96. PubMed ID: 26963458
[TBL] [Abstract][Full Text] [Related]
51. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
Moon DH; Maddahi J; Silverman DH; Glaspy JA; Phelps ME; Hoh CK
J Nucl Med; 1998 Mar; 39(3):431-5. PubMed ID: 9529287
[TBL] [Abstract][Full Text] [Related]
52. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose.
Wahl RL; Cody RL; Hutchins GD; Mudgett EE
Radiology; 1991 Jun; 179(3):765-70. PubMed ID: 2027989
[TBL] [Abstract][Full Text] [Related]
53. The relationship between FDG uptake in PET scans and biological behavior in breast cancer.
Shimoda W; Hayashi M; Murakami K; Oyama T; Sunagawa M
Breast Cancer; 2007; 14(3):260-8. PubMed ID: 17690502
[TBL] [Abstract][Full Text] [Related]
54. Correlation between quantified breast densities from digital mammography and 18F-FDG PET uptake.
Lakhani P; Maidment AD; Weinstein SP; Kung JW; Alavi A
Breast J; 2009; 15(4):339-47. PubMed ID: 19601942
[TBL] [Abstract][Full Text] [Related]
55. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
56. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings.
Crowe JP; Adler LP; Shenk RR; Sunshine J
Ann Surg Oncol; 1994 Mar; 1(2):132-40. PubMed ID: 7834438
[TBL] [Abstract][Full Text] [Related]
57. Effect of corrections for blood glucose and body size on [18F]FDG PET standardised uptake values in lung cancer.
Hallett WA; Marsden PK; Cronin BF; O'Doherty MJ
Eur J Nucl Med; 2001 Jul; 28(7):919-22. PubMed ID: 11504091
[TBL] [Abstract][Full Text] [Related]
58. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine.
Kaschten B; Stevenaert A; Sadzot B; Deprez M; Degueldre C; Del Fiore G; Luxen A; Reznik M
J Nucl Med; 1998 May; 39(5):778-85. PubMed ID: 9591574
[TBL] [Abstract][Full Text] [Related]
59. Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors.
Weber W; Bartenstein P; Gross MW; Kinzel D; Daschner H; Feldmann HJ; Reidel G; Ziegler SI; Lumenta C; Molls M; Schwaiger M
J Nucl Med; 1997 May; 38(5):802-8. PubMed ID: 9170450
[TBL] [Abstract][Full Text] [Related]
60. PET with L-[1-carbon-11]-tyrosine to visualize tumors and measure protein synthesis rates.
Kole AC; Pruim J; Nieweg OE; van Ginkel RJ; Hoekstra HJ; Schraffordt Koops H; Vaalburg W
J Nucl Med; 1997 Feb; 38(2):191-5. PubMed ID: 9025733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
